CAMbrella – Communique Platform on subjects associated with Complementary and Selection Drugs (CAM) in Europe

Rate this post

ANME targets at the Eu-wide reputation of CAM as one of those neatly being protection for purchasers and victims

Be informed further

A number of research approaches

Smartly being research is way over a question of efficacy, and as many CAM treatments don’t seem to be unmarried part based totally most commonly, this is further difficult compared to the investigation of a unmarried pharmaceutical

Be informed further

CAM and maximum cancers discussed among MEP’s

Two groups of MEP’s are encouraging the Eu Rate and the Eu Parliament to help integration of CAM into the healthcare of EU citizens

Be informed further

CAM in Germany

Many German MDs are working towards CAM, very frequently they attend postgraduate systems related to CAM, and the citizens benefit from excellent repayment possible choices.

Be informed further